Gene Therapy Clinical Trials
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Feraheme
- procedure: Magnetic Resonance Imaging (MRI) scan
Eligibility
INCLUSION CRITERIA
- Age 10 to 21 years
- Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis
- Informed consent with assent as appropriate.
EXCLUSION CRITERIA
- Contraindication to MRI
- Presence of metal implants
- Need for sedation or anesthesia
- Claustrophobia
- Hemosiderosis or hemochromatosis
- History of allergic reactions to similar compounds will be obtained and patients with
positive history of allergic reactions will be excluded from the study
- Females who are pregnancy or nursing
Ages Eligible for Study
10 Years - 21 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brittney Williams
650-736-3688
Not Recruiting